A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
NPS MedicineWise media release – bDMARDS September 2019 (002)
Discover more...
-
New campaign reveals blind spot for older Australians
Arthritis Australia is urging older Australians to look out for symptoms of silent inflammation that could put their eyesight at risk, and to speak to...
-
Musculoskeletal conditions, including arthritis, now the most costly disease group in Australia
The health system cost of musculoskeletal conditions, including arthritis, was $12.5 billion in 2015-16, up from $5.7 billion in 2008-09. The cost of these conditions...
-
A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
